Clinical Trial

Outcomes of Health Care Transition for AYA With a Cancer Predisposition

Study acronym: OnTRAC
Recruiting
View on ClinicalTrials.gov →
Summary
This observational study evaluates whether adolescents and young adults (AYAs) with a cancer predisposition syndrome (CPS) establish and maintain adult health care and continue CPS-specific cancer surveillance after graduating from pediatric care at St. Jude Children's Research Hospital (SJCRH). Participants will complete a Readiness Assessment and periodic surveys over 8 years post-graduation. Primary Objectives * To evaluate whether adolescents and young adults (AYAs) with a cancer predisposition syndrome (CPS) report they have established care with adult health care providers and pursue CPS-specific cancer surveillance within 1-year post-graduation from SJCRH. * To evaluate whether AYAs with CPS report they maintain care with adult health care providers and continue CPS-specific cancer surveillance 3 years post-graduation from SJCRH. Exploratory Objectives: * To evaluate whether AYAs with CPS report they continue to maintain care with adult health care providers and complete CPS-specific cancer surveillance longitudinally 5 years and 8 years post-graduation from St. Jude Children's Research Hospital (SJCRH). * To examine clinical correlates of establishing care with adult providers and initiating CPS-specific cancer surveillance post-graduation from SJCRH. * To identify the tumors diagnosed in AYAs with CPS after they graduate from SJCRH and determine how these tumors were identified (i.e., through specific surveillance tests or based on symptoms). * To identify barriers and facilitators AYAs face when establishing and maintaining adult health care and pursuing CPS-specific cancer surveillance.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-02
Trial Details
NCT Number NCT07456904
Lead Sponsor St. Jude Children's Research Hospital
Conditions Genetic Predisposition
Enrollment 56 participants
Start Date 2026-06-16
Primary Completion 2034-11 (estimated)
Study Completion 2037-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-18